Retraction of “Nanostructured Lipid Carriers Delivering Sorafenib to Enhance Immunotherapy Induced by Doxorubicin for Effective Esophagus Cancer Therapy”

Detalles Bibliográficos
Autores principales: Wang, Jia-Yang, Song, Ya-Qi, Peng, Jing, Luo, Hong-Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320148/
https://www.ncbi.nlm.nih.gov/pubmed/34337271
http://dx.doi.org/10.1021/acsomega.1c02888
_version_ 1783730592187154432
author Wang, Jia-Yang
Song, Ya-Qi
Peng, Jing
Luo, Hong-Lei
author_facet Wang, Jia-Yang
Song, Ya-Qi
Peng, Jing
Luo, Hong-Lei
author_sort Wang, Jia-Yang
collection PubMed
description
format Online
Article
Text
id pubmed-8320148
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-83201482021-07-30 Retraction of “Nanostructured Lipid Carriers Delivering Sorafenib to Enhance Immunotherapy Induced by Doxorubicin for Effective Esophagus Cancer Therapy” Wang, Jia-Yang Song, Ya-Qi Peng, Jing Luo, Hong-Lei ACS Omega American Chemical Society 2021-07-19 /pmc/articles/PMC8320148/ /pubmed/34337271 http://dx.doi.org/10.1021/acsomega.1c02888 Text en © 2021 American Chemical Society Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Wang, Jia-Yang
Song, Ya-Qi
Peng, Jing
Luo, Hong-Lei
Retraction of “Nanostructured Lipid Carriers Delivering Sorafenib to Enhance Immunotherapy Induced by Doxorubicin for Effective Esophagus Cancer Therapy”
title Retraction of “Nanostructured Lipid Carriers Delivering Sorafenib to Enhance Immunotherapy Induced by Doxorubicin for Effective Esophagus Cancer Therapy”
title_full Retraction of “Nanostructured Lipid Carriers Delivering Sorafenib to Enhance Immunotherapy Induced by Doxorubicin for Effective Esophagus Cancer Therapy”
title_fullStr Retraction of “Nanostructured Lipid Carriers Delivering Sorafenib to Enhance Immunotherapy Induced by Doxorubicin for Effective Esophagus Cancer Therapy”
title_full_unstemmed Retraction of “Nanostructured Lipid Carriers Delivering Sorafenib to Enhance Immunotherapy Induced by Doxorubicin for Effective Esophagus Cancer Therapy”
title_short Retraction of “Nanostructured Lipid Carriers Delivering Sorafenib to Enhance Immunotherapy Induced by Doxorubicin for Effective Esophagus Cancer Therapy”
title_sort retraction of “nanostructured lipid carriers delivering sorafenib to enhance immunotherapy induced by doxorubicin for effective esophagus cancer therapy”
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320148/
https://www.ncbi.nlm.nih.gov/pubmed/34337271
http://dx.doi.org/10.1021/acsomega.1c02888
work_keys_str_mv AT wangjiayang retractionofnanostructuredlipidcarriersdeliveringsorafenibtoenhanceimmunotherapyinducedbydoxorubicinforeffectiveesophaguscancertherapy
AT songyaqi retractionofnanostructuredlipidcarriersdeliveringsorafenibtoenhanceimmunotherapyinducedbydoxorubicinforeffectiveesophaguscancertherapy
AT pengjing retractionofnanostructuredlipidcarriersdeliveringsorafenibtoenhanceimmunotherapyinducedbydoxorubicinforeffectiveesophaguscancertherapy
AT luohonglei retractionofnanostructuredlipidcarriersdeliveringsorafenibtoenhanceimmunotherapyinducedbydoxorubicinforeffectiveesophaguscancertherapy

Ejemplares similares